Cargando…

Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been recommended as the first-line therapy for non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, acquired resistance to EGFR-TKIs is inevitable. Although immune checkpoint blockades (ICBs) tar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Di, Liu, Yangyang, Li, Xiaoting, Liu, Yiying, Yang, Qifan, Liu, Yuting, Wu, Jingjing, Tian, Chen, Zeng, Yulan, Zhao, Zhikun, Xiao, Yajie, Gu, Feifei, Zhang, Kai, Hu, Yue, Liu, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390822/ https://www.ncbi.nlm.nih.gov/pubmed/32793190 http://dx.doi.org/10.3389/fimmu.2020.01366

Ejemplares similares

The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study
por: Liu, Yuting, et al.
Publicado: (2021)

Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations
por: Iiizumi, Susumu, et al.
Publicado: (2019)

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response
por: Temko, Daniel, et al.
Publicado: (2018)

Clonal Architectures and Driver Mutations in Metastatic Melanomas
por: Ding, Li, et al.
Publicado: (2014)

Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas
por: Simon, Einav, et al.
Publicado: (2017)

Mutation-Derived Neoantigens for Cancer Immunotherapy
por: Castle, John C., et al.
Publicado: (2019)

Clinical, Mutational, and Transcriptomic Characteristics in Elderly Korean Individuals With Clonal Hematopoiesis Driver Mutations
por: Moon, Inki, et al.
Publicado: (2023)

Differential ion mobility mass spectrometry in immunopeptidomics identifies neoantigens carrying colorectal cancer driver mutations
por: Minegishi, Yuriko, et al.
Publicado: (2022)

Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer
por: Zhou, Jie, et al.
Publicado: (2019)

Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape
por: Maslah, Nabih, et al.
Publicado: (2023)

Cancer neoantigens and immunogenicity: mutation position matters
por: Capietto, Aude-Hélène, et al.
Publicado: (2020)

Somatic Mutations and Clonal Hematopoiesis as Drivers of Age-Related Cardiovascular Risk
por: Haring, Bernhard, et al.
Publicado: (2022)

Profiling of hepatocellular carcinoma neoantigens reveals immune microenvironment and clonal evolution related patterns
por: Li, Zhenli, et al.
Publicado: (2021)

Comprehensive Profiling Reveals Distinct Microenvironment and Metabolism Characterization of Lung Adenocarcinoma
por: Li, Chang, et al.
Publicado: (2021)

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design
por: Cai, Weijing, et al.
Publicado: (2018)

Mutation position is an important determinant for predicting cancer neoantigens
por: Capietto, Aude-Hélène, et al.
Publicado: (2020)

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy
por: Lin, Jing, et al.
Publicado: (2022)

Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
por: Li, Fenge, et al.
Publicado: (2021)

Application of metabolomics by UHPLC-MS/MS in diagnostics and biomarker discovery of non-small cell lung cancer
por: Liu, Yuting, et al.
Publicado: (2019)

TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection
por: Zhou, Zhan, et al.
Publicado: (2017)

Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets
por: Crosby, Erika J., et al.
Publicado: (2023)

Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer
por: Liang, Hongge, et al.
Publicado: (2022)

Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas
por: Yu, Guangyang, et al.
Publicado: (2021)

Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens
por: Grimaldi, Alessio, et al.
Publicado: (2020)

Full spectrum of clonal haematopoiesis‐driver mutations in chronic heart failure and their associations with mortality
por: Kiefer, Katharina C., et al.
Publicado: (2021)

P1337: IDENTIFICATION OF CLONAL HEMATOPOIESIS DRIVER MUTATIONS THROUGH IN SILICO SATURATION MUTAGENESIS
por: Demajo, Santiago, et al.
Publicado: (2023)

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
por: Efremova, Mirjana, et al.
Publicado: (2017)

Identification of non-mutated neoantigens presented by TAP-deficient tumors
por: Marijt, Koen A., et al.
Publicado: (2018)

Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
por: Chandran, Smita S., et al.
Publicado: (2022)

Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3
por: Tate, Tomohiro, et al.
Publicado: (2023)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets
por: Zhou, Si, et al.
Publicado: (2022)

Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
por: Jakobsen, Jan Nyrop, et al.
Publicado: (2018)

Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation
por: Kim, Eun Young, et al.
Publicado: (2019)

Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies
por: Saini, Sunil Kumar, et al.
Publicado: (2022)

Germline EGFR mutations in lung cancer (Review)
por: Liu, Minghui, et al.
Publicado: (2023)

Spleen‐targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma
por: Wu, Ming, et al.
Publicado: (2023)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy
por: Bai, Peng, et al.
Publicado: (2021)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
por: Kagawa, Yosuke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fvia7fvmuefgb0a40naqp7e1h8